10 hours Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms Fast Company
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumbling as much as 24% at one point in premarket trading …
X